钱氏姐弟如何“掏空”江苏吴中？ 占用资金有何隐秘通道？

Core Viewpoint - Jiangsu Wuzhong (SH600200) has been ordered to delist due to years of financial fraud, with its stock price plummeting over 70% since the announcement of its delisting period [1][3]. Group 1: Financial Fraud Details - Over the past four years, Jiangsu Wuzhong's chairman Qian Qunshan and vice-chairman Qian Qunying created a network of related transactions through at least six companies, inflating revenue by over 1.7 billion yuan [3][5]. - The China Securities Regulatory Commission (CSRC) found that three subsidiaries of Jiangsu Wuzhong engaged in non-commercial trade activities with related companies, leading to inflated revenue, operating costs, and profits [5][9]. - The inflated revenue figures for Jiangsu Wuzhong from 2020 to 2023 were 495 million yuan, 469 million yuan, 431 million yuan, and 377 million yuan respectively [9]. Group 2: Company Operations and Investigations - Investigations revealed that four out of five related companies had non-existent registered addresses, indicating potential fraudulent activities [5][7]. - Jiangsu Wuzhong's related parties occupied a total of 769 million yuan in funds, with significant amounts attributed to companies like Zhejiang Unode and Hangzhou Xintong [6][10]. - The company’s trade business was primarily conducted with entities that had questionable legitimacy, contributing billions in revenue while being linked to the fraudulent activities [10][11]. Group 3: Management Response and Accountability - During a shareholder meeting, management was questioned about a sudden cash flow drop of nearly 1 billion yuan, but responses were evasive [12]. - Qian Qunshan claimed he was not involved in the fraudulent trade activities, while other board members provided conflicting statements regarding their knowledge and involvement [13][14]. - The company’s stock price had previously surged due to the success of its medical beauty product, but the ongoing fraud has left investors with significant losses [15][16].